Good Morning Market Enthusiast,

While the market was processing the $30M raise,MAIA Biotechnology (NYSE: MAIA) just dropped a clinical "bomb" that confirms why the Probability of Success (PoS) was hiked to 35%. (14)
 

The News: MAIA reports Overall Survival (OS) exceeding TWO YEARS for eight patients in the ongoing THIO-101 Phase 2 trial. (14)
 

The Data Breakdown: (14)
 

• 33 Months Survival: One 3L (third-line) patient has now survived 33 months. In this heavily pre-treated population, the standard expected survival is only 5.8 months.
• 4 Patients > 30 Months: Four 2L (second-line) patients have surpassed the 30-month mark, nearly triple the standard of care (10.5 months).
• No Subsequent Therapy: These patients achieved these results without needing additional lines of treatment—proving that MAIA’s "immune memory" effect is real and persistent.
   

The Valuation Reality: This isn't just "good news"—it is a fundamental validation of the $10.27 price target. 
 

When you have a drug that can triple the survival rate of terminal lung cancer patients, a $1.50 institutional entry point starts to look like a historic mispricing.
 

Here's Why:
 

We have brought MAIA Biotechnology (NYSE: MAIA) to your attention before, but the story has fundamentally changed in the last 72 hours. We are no longer looking at a "speculative" biotech seeking a path; we are looking at a fully-funded, Phase 3 clinical leader that has just hit a massive de-risking milestone. (13)

(2)

1. The Institutional "Green Light": $33 Million Secured (5)(6)(7)(8)(9)(11)(12)(13)
 

The single biggest risk for small-cap biotech is the "going concern" — the fear that the company will run out of cash before the science proves out. That risk was officially extinguished last week.
 

• The Deal: MAIA closed a $30 million underwritten public offering (plus a $3M over-allotment) led by specialized healthcare backers.
• The Terms: These funds bought in at $1.50/share with a "clean" common share structure—meaning no warrants. In a market where companies often have to give away "sweeteners" to get cash, MAIA’s ability to raise $33M in pure equity proves that the "Smart Money" is betting on the clinical data, not a quick derivative flip.
• The Runway: This capital materially enhances near-term funding visibility, specifically securing the execution of the pivotal Phase 3 THIO-104 study.
   

2. The Science: Why Analysts Just Hiked the Odds (5)(6)(7)(8)(9)(11)(12)(13)

Science drives the money, and last week in Copenhagen at the European Lung Cancer Congress (ELCC) 2026, MAIA delivered.
 

• The Data: A poster presentation on the THIO-101 trial demonstrated "sustained therapeutic benefits" in relapsed Non-Small Cell Lung Cancer (NSCLC) patients, even after they stopped taking the drug.
• The "Trojan Horse" Effect: MAIA’s lead drug, THIO (ateganosine), is the only direct telomere-targeting agent in clinical development. It tricks cancer cells into destroying themselves from the inside out, then "primes" the immune system to keep hunting them.
   

The Re-Rating: Based on this clinical momentum and the new cash on the balance sheet, Diamond Equity Research has officially hiked the Probability of Success (PoS) from 25% to 35%. In oncology, a 10% jump in Phase 3 is the difference between a "maybe" and a "when."

(2)

3. The Valuation Gap: ~$1.50 vs. $10.27 (5)(6)(7)(8)(9)(11)(12)(13)
 

The "Peak FOMO" here isn't about chasing a ticker; it’s about the massive disparity between where the institutions just put their money and where the analysts see the fair value.
 

• Institutional Benchmark: Major healthcare funds just benchmarked this company at $1.30.
• The Illustrative Target: Diamond Equity Research maintains a valuation of $10.27.
• The Window: This represents a massive upside gap that exists because the market is still processing the scale of the recent capital raise.
   

4. 2026: The Year of the Catalyst (5)(6)(7)(8)(9)(11)(12)(13)
 

With the bank account full and the Phase 3 trial live, the remainder of 2026 is a "catalyst rich" environment:
 

• Interim Phase 3 Data: Initial measures of efficacy (Disease Control Rate and Overall Response Rate) are expected this year.
• Fast Track Acceleration: MAIA is using its FDA Fast Track status to potentially move toward Accelerated Approval, which could bring THIO to the $50 billion immunotherapy market much sooner than previously modeled.
• Pipeline Expansion: Commencement of Phase 1 trials for "second-generation" telomere-targeting molecules developed entirely in-house.

The Verdict

We’ve been telling you the science was real—now the balance sheet is real too. The institutional "buy-in" at $1.50 provides a clear floor for market enthusiasts, while the $10.27 target highlights the explosive potential as Phase 3 data begins to read out.

If you missed our previous updates, this is the version of MAIA you’ve been waiting for: The science is validated, the cash is in the bank, and the Phase 3 breakthrough is in motion.

To your success,

Max Masters

Co-founder, Market Tips Newsletter

Sources:
1. https://bit.ly/3LqsROV
2. https://bit.ly/49Pbnnt
3. https://bit.ly/4sSDZ84
4. https://bit.ly/3LRvw4g
5. https://ir.maiabiotech.com/
6. https://maiabiotech.com/
7. https://finance.yahoo.com/quote/MAIA/
8. https://finance.yahoo.com/news/maia-biotechnology-advances-ateganosine-cancer-151500344.html
9. https://finance.yahoo.com/news/diamond-equity-research-releases-note-130000503.html

10. https://finance.yahoo.com/news/maia-biotechnology-phase-3-momentum-134500266.html
11. https://finance.yahoo.com/news/maia-biotechnology-announces-closing-30-210000173.html
12. https://finance.yahoo.com/news/diamond-equity-research-releases-note-210000621.html
13. https://finance.yahoo.com/markets/stocks/articles/diamond-equity-research-releases-note-120000005.html

Momentum Media LLC has not been paid for today's profile on MAIA Biotechnology Inc. (MAIA:US). Momentum Media LLC has been previously hired for a period beginning on 03/26/2026 and ending on 03/27/2026 (the “Campaign”) to publicly disseminate information about MAIA Biotechnology Inc. (MAIA:US). Momentum Media LLC has been compensated $7,500.00 and are owed an additional $0 for the Campaign. To date, we have been paid $122,100.00. Please read Momentum Media LLC’s complete disclaimer at https://markettips.net/disclaimer/ which includes important information. Emojis, graphics and/or images used herein have no specific or implied meaning, and are used for artistic purposes only. Nothing contained herein is financial advice. Momentum Media LLC is not an analyst, st.o.ck broker, financial adviser or st.o.ck picker nor is it qualified to act in the capacity of any of the foregoing. Information herein is a paid advertisement and should not be relied upon as accurate or complete.